According to a new report published by Allied Market Research, titled, “CAR T-Cell therapy Market,” The car t-cell therapy market was valued at $1.7 billion in 2021, and is estimated to reach $6.1 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞:
https://www.alliedmarketresearch.com/request-sample/17358
Key Findings of the Study –
- By drug type, the axicabtagene ciloleucel segment held the largest share in the CAR T-cell therapy market in 2021.
- By indication, the lymphoma segment held the largest share in the CAR T-cell therapy market in 2021.
- By end user, the cancer centers segment is expected to show the fastest market growth during the forecast period.
- Region-wise, North America held the largest market share in 2021.
Based on the forecast, the lymphoma segment will generate the most revenue in 2021 due to the high number of CAR T-cell therapies approved for the treatment of various types of lymphoma and the large number of target populations. The acute lymphocytic leukemia segment is expected to witness the highest CAGR during the forecast period, due to the increase in CAR T-cell therapies for the treatment of all people and the expected launch of these drugs for the treatment of LAL.
On the basis of the end user, the hospital sector is the largest contributor to the market revenue in 2021, due to factors such as more efficient rooms, higher purchasing power and increased patient acceptance. The cancer treatment segment is expected to witness the highest CAGR during the forecast period, due to the availability of various treatment options and the increase in the number of cancer sites in some developing countries.
♦ 𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/purchase-enquiry/17358
Region-wise, in CAR-T cell therapy industry, North America generated higher revenue in 2021, owing to strong presence of key players and availability of approved therapeutics with higher adoption of CAR T-cell therapies. Asia-Pacific is expected to witness highest CAGR during the forecast period owing to rise in awareness regarding CAR T-cell therapy, expected launch of CART drugs, and rise in the number of target population.
Key Market Players –
Major key players that operate in the industry are Autolus, Bluebird Bio-Inc., Bristol-Myers Squibb, Caribou Biosciences Inc., Cartesian Therapeutics, Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Merck & Co. Inc., Miltenyi Biotech, Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc.
By Region –
North America (U.S., Canada, Mexico)
Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Asia-Pacific (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
♦ 𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐡𝐢𝐬 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/checkout-final/55823076f71fbe02258caf5b89d2c1f7
Frequently Asked Questions?
Q1. What is the total market value of global car t-cell therapy market?
Q2. Which market holds the maximum market share of the global car t-cell therapy market?
Q3. What will be global car t-cell therapy market growth in 2030?
Q4. What are the key trends in the global car t-cell therapy market?
Q5. What are the key growth strategies of global car t-cell therapy market players?
Q6. How the company profile has been selected?
About Us –
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com